Jennifer Stern, MD
Neurology · Rochester, MNNPI 1326218157
Payments from drug & device makers
Across 38 payments — averaging $17.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$96
- AbbVie$62
- Amgen$61
- Adamas Pharmaceuticals, Inc.$60
- Supernus Pharmaceuticals, Inc.$59
- Lilly USA, LLC$51
- plus $277 from 12 others
What the payments were for
- Consulting fees$213%
- Speaking & faculty fees$193%
- Food & beverage$62694%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 6 | $96 |
| AbbVie | 4 | $62 |
| Amgen | 3 | $61 |
| Adamas Pharmaceuticals, Inc. | 3 | $60 |
| Supernus Pharmaceuticals, Inc. | 3 | $59 |
| Lilly USA, LLC | 3 | $51 |
| Sanofi | 3 | $47 |
| Lundbeck LLC | 2 | $34 |
| Teva Pharmaceuticals USA, Inc. | 2 | $28 |
| AstraZeneca | 1 | $26 |
| EMD Serono, Inc. | 1 | $24 |
| Promius Pharma LLC | 1 | $21 |
| Merz North America, Inc. | 1 | $20 |
| Acorda Therapeutics, Inc | 1 | $19 |
| Novartis | 1 | $18 |
| Grifols USA, LLC | 1 | $16 |
| W. L. Gore & Associates, Inc. | 1 | $14 |
| UCB, Inc. | 1 | $11 |
How this compares
$666 in reported general payments places this provider in the 60th percentile of 434 neurology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Emgality PenGalcanezumab-Gnlm | 13 | $10,451 |
| Lamotrigine | 16 | $161 |
Paid to pharmacies, not to this prescriber.
Other neurology in Rochester
- Sean PittockRochester$3.2M
- Miguel Paz SoldanRochester$2.4M
- Ryan TownleyRochester$2M
- Eoin FlanaganRochester$1.7M
- David KnopmanRochester$1.6M
- Partha GhoshRochester$1.3M
- Wolfgang SingerRochester$1.3M
- Peter DyckRochester$1M
- James BowerRochester$820K
- Jonathan Graff-RadfordRochester$713K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.